Yoshida H, Sato M, Watanabe S, Nishimaki T, Morito T, Kasukawa R, Nakai M
Tohoku J Exp Med. 1983 May;140(1):73-9. doi: 10.1620/tjem.140.73.
The highest mean value of the serum C1q concentrations among chronic liver diseases was obtained in patients with liver cirrhosis (LC). C1q serum levels seemed to increase along the progression of liver damage. Serum levels of C1q and CH50 in patients with LC and systemic lupus erythematosus (SLE) were simultaneously estimated. No correlation between C1q and CH50 levels was observed in LC sera, while a significant correlation was demonstrated in SLE sera. It could be suggested that the mechanism for the low CH50 in LC sera seemed different from that in SLE sera, and that the activation of classical complement pathway was not the predominant cause in LC sera. Correlations of serum levels between immune complexes and C1q were examined in patients with LC and SLE. It could be deduced from the results of a positive correlation in LC sera and the reverse tendency in SLE sera that the significances of C1q and immune complexes in LC sera differed from those in SLE sera.
慢性肝病患者中,血清C1q浓度的最高均值出现在肝硬化(LC)患者中。C1q血清水平似乎随着肝损伤的进展而升高。同时对LC患者和系统性红斑狼疮(SLE)患者的C1q和CH50血清水平进行了评估。在LC血清中未观察到C1q与CH50水平之间的相关性,而在SLE血清中则显示出显著相关性。可以推测,LC血清中CH50降低的机制似乎与SLE血清中的不同,并且经典补体途径的激活不是LC血清中的主要原因。对LC和SLE患者免疫复合物与C1q之间的血清水平相关性进行了研究。从LC血清中的正相关结果和SLE血清中的相反趋势可以推断,LC血清中C1q和免疫复合物的意义与SLE血清中的不同。